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A B S T R A C T
Purpose: We aimed to deﬁne the possible risk factors for acute and remote seizures in patients with
cerebral vein and sinus thrombosis (CVST).
Method: Ninety-four patients were recruited prospectively at Al-Zahra Hospital, Isfahan, Iran, between
April 2007 and April 2012. To identify seizure predictors, we compared demographic, clinical and
imaging factors between patients with or without acute and remote seizures.
Results: Of the 94 patients, 32 (34%) experienced at least one seizure after CVST development. Bivariate
analysis showed a signiﬁcant association of remote seizure with loss of consciousness at presentation
(P = 0.05, OR: 5.11, 95%CI: 1.07–24.30), supratentorial lesions (P = 0.02, OR: 9.04, 95%CI: 1.04–78.55),
lesions in the occipital lobe (P = 0.00, OR: 12.75, 95%CI: 2.28–71.16), lesions in the temporal and parietal
lobes, thrombophilia (P = 0.03, OR: 5.87, 95%CI: 1.21–28.39), seizure in the acute phase (P = 0.00, OR:
13.14, 95%CI: 2.54–201.2) and sigmoid sinus thrombosis (P = 0.00, OR: 12.5, 95%CI: 2.23–69.79). Seizures
in the acute phase were also more common in patients with paresis (P = 0.00, OR: 4.88, 95%CI: 1.91–
12.46), hemorrhagic lesions indicated by imaging (P = 0.02, OR: 2.77, 95%CI: 1.08–7.10), supratentorial
lesions, lesions in the frontal (P = 0.01, OR: 3.81, 95%CI: 1.28–11.31) and parietal lobes (P = 0.00, OR: 5.16,
95%CI: 2–13.29), thrombophilia and history of miscarriage (P = 0.03, OR: 2.91, 95%CI: 1.07–7.91). No
factor predicted acute or remote seizure in a multiple logistic regression analysis.
Conclusion: Our results demonstrate that seizure development in the acute phase is the most signiﬁcant
factor for development of remote seizure. Parenchymal lesions in the supratentorial area were also found
to be associated with both acute and remote seizures. However, no factor was predictive of acute or
remote seizures in a multivariate analysis.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Cerebral vein and sinus thrombosis (CVST) is an uncommon type
of stroke that mostly presents in young and middle-aged adults.
Among all symptoms associated with CVST, seizures are more
speciﬁc to CVST than to other types of stroke.1–3Approximately one-
third of CVST patients have been reported to develop focal or
generalized epileptic seizures before the conﬁrmation of CVST
diagnosis.4 Seizures can develop during different periods of the
disease’s course and accordingly are categorized as either ‘‘acute
seizures’’ (AS), which take place before the diagnosis or during the
ﬁrst 2 weeks afterward, or as ‘‘remote seizures’’ (RS), which occur in
the years following CVST development.4 Seizures are commonly
reported to occur in the ﬁrst year after CVST development.5,6 Thus,* Corresponding author at: Neurology Department, Al-Zahra Hospital, Isfahan,
Iran. Tel.: +98 9131147179.
E-mail address: mosaadatnia@yahoo.com (M. Saadatnia).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.10.011whether to initiate anticonvulsant treatment for all CVST patients or
to wait for a seizure to occur before starting treatment is a vital issue
that requires attention. Finding predictors of acute and remote
seizures may help neurologists to decide in whom treatment with
prophylactic antiepileptic drugs (AED) would be beneﬁcial, thus
reducing the possible harm of seizures. However, few studies
concerning the predictors of acute seizures have been conducted to
date, and even fewer have been conducted to identify the possible
predictors of remote seizures.1,5,7–12
We aimed to deﬁne the possible predictors of remote and acute
seizures in patients with CVST, which may help determine under
what circumstances initiating AED treatment is most beneﬁcial.
2. Methods
2.1. Patients and methods
We designed a prospective cohort study in patients who were
admitted with CVST to Al-Zahra Hospital, Isfahan, Iran from Aprilvier Ltd. All rights reserved.
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neurologists according to the diagnostic criterion published by
Bousser et al.8 To ensure an accurate diagnosis, all three types of
brain imaging techniques, including cerebral topography (CT),
magnetic resonance imaging (MRI) and magnetic resonance
venography (MRV), were performed for each patient. We excluded
individuals for whom complete brain imaging (CT, MRI and MRV)
was not completed. Due to a lack of equipment, we did not conduct
cerebral topography venography (CTV) for any of the patients. In
addition, we excluded patients with a history of AED treatment or
epilepsy. We also excluded those with any form of severe
systematic or neurological diseases. Informed consent was
obtained from all patients enrolled in this study after clarifying
the terms and conditions as well as the study procedures. Those
who refused to complete the informed consent form were not
included in the survey.
Upon admission, the demographic characteristics of the
patients and their previous medical history were recorded. In
addition, a complete neurological examination, laboratory tests
and further brain imaging were performed to evaluate the
following risk factors: gender, age, oral contraceptive use, history
of miscarriage, CVST in pregnancy or puerperium, motor deﬁcits,
papillary edema, loss of consciousness, thrombophilia, positive
vasculitis tests, abnormal hematologic conditions, hemorrhagic
lesions indicated by imaging, lesions in different brain tentorial
areas (supratentorial or infratentorial), abnormal lesions on
imaging in various brain lobes (frontal, temporal, parietal or
occipital) and types of sinus thrombosis (sagittal sinus, lateral
sinus, transverse sinus, sigmoid sinus, deep sinus and all sinuses).
To deﬁne the various types of seizures (acute and remote), we
applied the method used in a similar study by the Cerebral Venous
Thrombosis Portuguese Collaborative Study Group [Venoport] in
2003 [7]. Acute seizures were also divided into ‘‘presenting
seizures’’, which is the term applied to seizures occurring before
diagnosis, and ‘‘early seizures’’, which are seizures that occur in the
ﬁrst 2 weeks after diagnosis. Patients were followed-up one month
after discharge and attended regular check-ups every 6 months to
determine whether they had developed RS. Patients who did not
attend scheduled appointments were followed-up through tele-
phone contact.
Patients who experienced more than one remote seizure after
discharge were considered to have epilepsy. Anti-epileptic
treatment protocols, in terms of the type and dosage of AED,
were not identical in all patients who developed seizures.
2.2. Statistical analysis
We compared demographic, clinical and imaging factors among
patients with or without acute and remote seizures. We applied x2
tests for bivariate analysis (with Yates’s correction when neces-
sary). Student’s t-test was used to analyze continuous data. A
signiﬁcant probability value (P value) was considered to be <0.05.
To identify seizure predictors, we applied multivariate analysis
[logistic-regression analysis (backward model)]. Variables with a
signiﬁcant P value in bivariate analysis were incorporated as
predictors in the model. Statistical analyses were performed using
SPSS software (version 17).
3. Results
3.1. General information
From April 2007 to April 2012, 95 patients were admitted with
the diagnosis of CVST to Al-Zahra Hospital, Isfahan, Iran. During
patient retrieval, we excluded one patient due to a history
of epilepsy and AED treatment. Ninety-four patients (16 male and78 female, mean age: 37.19, SD: 11.38) were included in this study,
among whom one had experienced CVST for the second time.
During hospitalization, 75 of these 94 patients were treated with
anticonvulsant drugs. Phenytoin was administered in 58 patients
(60.4%), valproate in 19 (19.8%), carbamazepine in 8 (8.3%),
phenobarbital in 2 (2.1%) and either lamotrigine or gabapentin in
only 1 patient.
After discharge, 63 individuals were followed, whereas others
were lost to follow-up. Forty-two patients presented for interview,
and 21 were followed-up via phone call, with follow-up lasting for
a mean of 28.4 months (median = 27.5 months; range = 1–57
months; one patient with remote seizure died at the end of one
month of follow-up). After discharge, of the 63 patients who had
been followed-up, 41 were treated with AED. All patients with
acute seizure had received AED during hospitalization and were
also prescribed AED after discharge. At discharge, 14 patients
(21.87%) were being treated with phenytoin, 25 patients (39.06%)
with valproate, 10 patients (15.62%) with gabapentin, 4 patients
(6.25%) with carbamazepine, 2 patients (3.12%) with lamotrigine
and ﬁnally 1 with phenobarbital.
3.2. Acute seizure characteristics
Of the 94 patients, 32 individuals (34%) experienced at least one
seizure based on CVST. Seizures were generalized in 20 patients
(21.2%) and focal in 7 patients (7.4%), and both types presented in 5
patients (5.3%). We recorded one patient who developed an episode
of status epilepticus during the acute phase. There were 18 patients
(19.1%) who experienced a presenting seizure before the diagnosis
was conﬁrmed, and 20 individuals (21.3%) had early seizures in the 2
weeks after conﬁrmation of the CVST diagnosis. Six patients (6.3%)
had recurrent early seizures after a presenting seizure.
3.3. Remote seizure characteristics
Sixty-three individuals were followed-up, whereas 31 patients
were unreachable after discharge. Among these 63 patients, 8
(12.6%) faced RS at long-term follow-up (mean: 15th months after
onset, range = 1–50, SD = 16.68). Five patients (7.9%) developed RS
(ﬁrst seizure for multiple seizures) during the ﬁrst year after
discharge. In addition, two patients had RS during the 2 months
following admission. Only one patient experienced RS during
hospitalization. RS were generalized in ﬁve patients and focal in two
patients, and both types presented in one patient. RS in one patient
were subsequent to a cesarean delivery (in the absence of PIH) four
years following the development of CVST. In another patient, RS
occurred against a background of intracerebral hemorrhage 10
months after discharge. Following discharge, four patients (6.3%)
suffered from multiple RS and were diagnosed with epilepsy. In
addition, among all patients with RS (eight patients), only one had no
history of presenting or early seizures in the acute phase. Of the
seven remaining patients (who experienced RS), four presented with
a presenting seizure, two were observed to have early seizures and
one had developed both presenting and early seizures.
3.4. Factors associated with acute seizures (including early and
presenting seizures)
Acute seizures were more common in patients with paresis,
hemorrhagic lesions indicated by imaging, supratentorial lesions,
lesions in the frontal and parietal lobes, thrombophilia and a
history of miscarriage (Table 2). Supratentorial lesions were the
most signiﬁcant factor associated with AS (P value = 0.00, OR: 5.96,
CI: 2.22–15.98). Lesions in the parietal lobe were also highly
associated with acute phase seizures (P value = 0.00, OR: 5.16, CI:
2–13.29). Twenty-eight patients (29.2%) presented with lesions in
Table 1
Clinical and imaging factors in association with remote seizure.
Variable Remote seizure P OR 95%CI
No (n = 55) Yes (n = 8)
N Percent N Percent
Age >37 22 40.0 3 37.5 0.59 0.87 0.18–4.03
Sex (male) 6 10.9 2 25 0.26 2.72 0.44–16.65
Loss of consciousness 9 16.4 4 50 0.05 5.11 1.07–24.30
Any paresis 20 36.4 6 75 0.04 5.25 0.96–28.5
Papilledema 33 60 3 37.5 0.20 0.40 0.08–1.84
Acute seizure 13 23.6 7 87.5 0.00 13.14 2.54–201.2
Sagital sinus 40 72.7 7 87.5 0.34 2.62 0.29–23.16
Lateral sinus 40 72.7 8 100 0.09 1.20 1.05–1.36
Transvers sinus 40 72.7 8 100 0.09 1.20 1.05–1.36
Deep sinus 3 5.6 2 25 0.12 5.66 0.78–41
Straight sinus 10 18.5 4 50 0.06 4.40 0.93–20.66
Sigmoid sinus 4 7.4 4 50 0.00 12.5 2.23–69.79
All sinuses 2 3.6 2 25 0.07 8.83 1.04–74.63
Any hemorrhagic lesion 12 21.8 4 50 0.10 3.58 0.77–16.49
Any supratentorial lesion 24 43.6 7 87.5 0.02 9.04 1.04–78.55
Any infratentorial lesion 5 9.1 2 25 0.21 3.33 0.52–21.10
Any lesion in parietal lobe 13 23.6 5 62.5 0.03 5.38 1.13–25.64
Any lesion in frontal lobe 5 9.1 3 37.5 0.057 6 1.09–32.88
Any lesion in occipital lobe 4 7.3 4 50 0.00 12.75 2.28–71.16
Any lesion in temporal lobe 9 16.4 4 50 0.05 5.11 1.07–24.30
Oral contraceptive use 33 60 5 62.5 0.60 1.11 0.24–5.12
Pregnancy/puerperium 10 18.2 2 25 0.47 1.5 0.26–8.55
Thrombophilia 8 14.5 4 50 0.03 5.87 1.21–28.39
Hematologic conditions 2 3.6 1 12.5 0.33 3.78 0.3–47.36
Positive vasculitis tests 2 3.6 1 12.5 0.33 3.78 0.3–47.36
AED during hospitalization 41 74.5 8 100 0.18 1.19 1.05–1.35
AED after discharge 28 60.9 7 87.5 0.23 4.5 0.51–39.70
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and 5 (5.2%) had lesions in three lobes. We found that developing
lesions that were limited to a single lobe were signiﬁcantly
associated with AS (P = 0.03, OR: 2.88, CI: 1.14–7.25), whereas
others with two or three affected brain lobes showed no
association. According to logistic multiple regression analysis,
no factor was predictive for AS.Table 2
Clinical and imaging factors in association with acute seizure (including early and pre
Variable Acute siezure 
No (n = 63) Yes (
n Percent n 
Age >37 31 50 16 
Sex (male) 11 17.5 5 
Loss of consciousness 12 19 7 
Any paresis 21 33.3 22 
Papilledema 35 55.6 12 
Sagital sinus 46 74.6 25 
Lateral sinus 50 79.4 24 
Transvers sinus 50 79.4 24 
Deep sinus 3 4.7 4 
Straight sinus 15 23.8 6 
Sigmoid sinus 5 7.9 3 
All sinus 2 3.2 3 
Any hemorrhagic lesion 13 20.6 13 
Any supratentorial lesion 23 36.5 24 
Any infratentorial lesion 7 11.1 4 
Any lesion in parietal lobe 12 19 17 
Any lesion in frontal lobe 7 11.1 10 
Any lesion in occipital lobe 6 9.5 4 
Any lesion in temporal lobe 8 12.7 8 
Oral contraceptive use 35 55.6 15 
Pregnancy/puerperium 6 9.5 7 
Thrombophilia 4 6.3 9 
Hematologic conditions 6 9.5 4 
Positive vasculitis tests 3 4.8 2 
Miscarriage 10 15.9 11 3.5. Factors associated with remote seizures
Bivariate analysis showed a signiﬁcant association of RS in
patients with loss of consciousness at presentation, supratentorial
lesions, lesions in the occipital, temporal and parietal lobes,
thrombophilia, AS (early or presenting seizure) and sigmoid sinus




51.6 0.52 1.06 0.45–2.52
16.1 0.56 0.9 0.28–2.89
22.6 0.44 1.24 0.43–3.54
71 0.00 4.88 1.91–12.46
38.7 0.09 0.50 0.21–1.21
77.4 0.48 1.16 0.42–3.22
77.4 0.51 0.89 0.31–2.52
77.41 0.51 0.89 0.31–2.52
12.9 0.24 4.42 0.38–50.89
20 0.44 0.8 0.27–2.32
10 0.5 1.28 0.28–5.79
9.7 0.19 3.26 0.51–20.66
41.9 0.02 2.77 1.08–7.10
77.4 0.00 5.96 2.22–15.98
12.9 0.52 1.18 0.31–4.39
54 0.00 5.16 2–13.29
32.3 0.01 3.81 1.28–11.31
12.9 0.43 1.40 0.36–5.40
25.8 0.09 2.39 0.8–7.14
48.4 0.33 0.75 0.31–1.77
22.6 0.08 2.77 0.84–9.10
29 0.01 4.60 1.43–15.72
12.9 0.43 1.40 0.36–5.40
6.5 0.53 1.37 0.21–8.71
35.5 0.03 2.91 1.07–7.91
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2.54–201.2). Of the different cerebral lobes, the occipital lobe had
the most signiﬁcant association with lesions (P value = 0.00, OR:
12.75, CI: 2.28–71.16). There was no signiﬁcant relationship
between the number of affected brain lobes and the occurrence of
RS (P value < 0.05). The CT and MRI scans of all patients with RS
revealed areas with patchy ﬁbrosclerosis that broadly involved the
cerebral parenchyma. Although we did not use a speciﬁc indicator
to measure levels of cerebral sclerosis in all CVST patients, this
level was considerably high in patients with RS. Moreover,
thrombosis in the sigmoid sinus was the only type of sinus
signiﬁcantly associated with RS (P value = 0.00, OR: 12.5, CI: 2.23–
69.79). However, the associations of the lateral sinus thrombosis (P
value = 0.09, OR: 1.20, CI: 1.05–1.36) and thrombosis in all sinuses
(P value = 0.07, OR: 8.83, CI: 1.04–74.63) with RS were nearly
signiﬁcant. Logistic multiple regression analysis indicated no
factor predictive of RS. In addition, RS was found to have no relation
with AED prescription, neither during hospitalization nor after
discharge (Table 1).
To identify any possible confounders due to the high attrition
rate during follow-up (25 out of 94 patients, 26%), we compared all
risk factors among patients who were followed-up and those who
were lost to follow-up. Age (P value = 0.01, OR: 0.26, CI: 0.09–0.74)
and miscarriage (P value = 0.01, OR: 9.79, CI: 1.24–77.38) differed
signiﬁcantly between the two groups. Subsequent sensitivity
analysis showed age as a possible factor associated with RS
(P = 0.00, CI: 1.41–8.04) and (P = 0.47, CI: 0.11–2.32). However,
having a history of miscarriage was not associated with developing
RS (P = 0.21, CI: 0.16–1.39) and (P = 0.07, CI: 0.92–17.90).
3.6. Effect on outcome
During our study, seven patients (7.4%) died during hospitali-
zation and one died 2 years after discharge for an unknown reason.
Among 32 patients who experienced at least one seizure during
our study, the rate of death was 12.5% (4/32), whereas only 6.45%
(4/62) of patients without seizures died. We found no relationship
between seizure and death (P value = 0.26, OR: 2.07, CI: 0.48–8.89).
Neither AS nor RS were discretely associated with mortality rate.
Among patients who developed RS, only one died, during the
month following CVST onset. There were no deaths due to status
epilepticus seizures.
4. Discussion
Approximately 33% of patients developed seizures in the acute
phase of CVST, but only 12.6% experienced RS during subsequent
years [most frequently in the ﬁrst year (7.6%)]. Almost all patients
who experienced RS had had a seizure at disease onset.
Accordingly, an AS at CVST onset was the factor most strongly
associated with seizure development in the long term. On the other
hand, supratentorial-parenchymal lesions observed in brain
imaging were reported to be strongly associated with both remote
and acute seizures. This study represents the ﬁrst time that
supratentorial lesions have been proposed as a strong risk factor
for RS. Only a few studies have attempted to determine the
predictors of RS. In 2012, Kaila et al. found no predictive factor for
long-term seizure development.11 In another study in 2003, the
Venoport group found that AS and hemorrhagic lesions were more
common in patients with late seizures. Only hemorrhagic lesions
were shown to be a predictive factor for RS by means of logistic
regression.7 AS in our study contributed to RS; in contrast,
hemorrhage was not considered to be a signiﬁcant risk factor for
seizures in the chronic phase. However, in our logistic multiple
regression analysis, we found no predictor for RS.Furthermore, we found supratentorial lesions to be associated
with RS. This ﬁnding is particularly novel because studies such as
the Venoport study did not evaluate the role of parenchymal
lesions in different tentorial areas in predicting RS. The Interna-
tional Study of Cerebral Vein and Sinus Thrombosis (ISCVT) study,
the largest study ever performed regarding acute phase seizures,
proposed that supratentorial-parenchymal lesions are the most
important predictor for early seizures. Cerebral parenchymal
lesions, particularly when located supratentorially, may present
cortical involvement with an increased risk of seizures.
Loss of consciousness at CVST onset and thrombophilia are
other previously unreported risk factors that were associated with
RS in our study. We also evaluated the role of cerebral–
parenchymal lesions in different brain lobes. Frontal and parietal
lobe lesions were associated with Acute seizures, whereas parietal,
temporal and occipital lobe lesions were associated with RS
seizures. Moreover, the occipital lobe had the most signiﬁcant
association with RS. Only one previous study (Kalita et al.) has
evaluated lesions in different brain lobes; no relationship with RS
was found,11 although the authors reported that frontal and
parietal lobe lesions were a predictor for presenting seizures.
We also found lesions that encompassed multiple brain lobes,
which might cause CVST patients to present more RS. However,
there was no association between RS and the number of brain lobes
affected by parenchymal lesions. As a result and because of the
complexity it may cause, the risk of cerebral lesions within
multiple brain lobes was ignored.
Among the different types of sinus thrombosis, sigmoid sinus
thrombosis was correlated with RS. Thrombosis in other sinuses
showed no signiﬁcant association with AS or RS. The Venoport
group also found no relationship between RS and sinus type.7
Temporal lobe structures are highly sensitive to insults and are
commonly involved in epileptogenesis. Hippocampal sclerosis is
the most common type of neuropathological damage observed in
individuals with temporal lobe epilepsy (TLE).13,14 Surprisingly, we
observed patchy ﬁbrosclerotic tissue distributed widely through-
out the brain parenchyma of all patients who experienced remote
seizures. Thus, further longitudinal cohorts are needed to evaluate
cerebral sclerosis in patients with and without RS.
A limitation of our study was the limited number of patients (94
patients), especially patients who experienced RS (8 patients), and
the even smaller number of patients who were followed-up in the
long term (63 patients).
To measure the probable attrition bias, we compared different
risk factors between followed and unfollowed patients, and found
that age and having a history of miscarriage differed signiﬁcantly.
However, only age was found to act as a possible confounder
during further analysis. In contrast, previous studies found no
evidence that age plays any role in developing any type of seizure.
However, it should be noted that our patients were recruited from
a single healthcare center, which would eliminate the bias induced
by different diagnostic and therapeutic protocols used in different
centers.
According to bivariate analysis, there was no signiﬁcant
association between AED prescription and RS. However, the dose,
duration or type of antiepileptic drugs were not evaluated in
current study. Finally, the confounding effects of AED were
inevitable for moral and practical reasons.
Our study provided no evidence that seizures increase the risk
of mortality, in contrast to previous observations [5,7].
5. Conclusion
In conclusion, patients with seizures in the acute phase and
supratentorial lesions at the time of initial brain imaging are more
likely to develop remote seizures after CVST. Other factors such as
V. Davoudi et al. / Seizure 23 (2014) 135–139 139loss of consciousness, occipital lobe lesions, thrombophilia and
sigmoid sinus thrombosis can provide more support for AED
administration. Additionally, further studies concerning the role of
cerebral ﬁbrosclerosis in predicting RS are strongly recommended.
Larger studies should be performed to reassess the predictive
factors for RS, and AED administration remains a key issue in CVST
management.
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